287 related articles for article (PubMed ID: 26266428)
21. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model.
Sella R; Gal-Or O; Livny E; Dachbash M; Nisgav Y; Weinberger D; Livnat T; Bahar I
Exp Eye Res; 2016 May; 146():224-232. PubMed ID: 27020759
[TBL] [Abstract][Full Text] [Related]
24. H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascularization by inducing endothelial apoptosis and arresting the cell cycle.
Sun Y; Su L; Wang Z; Xu Y; Xu X
BMC Cell Biol; 2013 Feb; 14():8. PubMed ID: 23433118
[TBL] [Abstract][Full Text] [Related]
25. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
26. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M
Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
[TBL] [Abstract][Full Text] [Related]
27. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
Bucher F; Parthasarathy A; Bergua A; Onderka J; Regenfuss B; Cursiefen C; Bock F
Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of pathological corneal neovascularization by a small peptide derived from human apolipoprotein (a) Kringle V.
Wang Z; Zhao H; Ma JX; Xu X
Cornea; 2014 Apr; 33(4):405-13. PubMed ID: 24452210
[TBL] [Abstract][Full Text] [Related]
29. Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits.
Kim RY; Chung SK; Kim MS; Ra H
Cornea; 2016 Dec; 35(12):1615-1620. PubMed ID: 27684458
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Topical Pigment Epithelium-Derived Factor (PEDF) with Topical Bevacizumab for Accelerating the Regression of Corneal Neovascularization in an Experimental Model of Rabbit Corneal Angiogenesis.
Mahmoudzadeh R; Heidari-Keshel S; Mehrpour M; Asadi Amoli F; Aghajanpour L; Lashay A
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1471-1477. PubMed ID: 32407187
[No Abstract] [Full Text] [Related]
31. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Topical Low-Molecular-Weight Heparin-Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization.
Moon CH; Moon BG; Kim JY; Kim MJ; Tchah H
Cornea; 2017 Apr; 36(4):497-501. PubMed ID: 27941385
[TBL] [Abstract][Full Text] [Related]
33. KH902, a recombinant human VEGF receptor fusion protein, reduced the level of placental growth factor in alkali burn induced-corneal neovascularization.
Zhou AY; Bai YJ; Zhao M; Yu WZ; Li XX
Ophthalmic Res; 2013; 50(3):180-6. PubMed ID: 24008241
[TBL] [Abstract][Full Text] [Related]
34. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S
Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
[TBL] [Abstract][Full Text] [Related]
35. Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model.
Gore A; Horwitz V; Cohen M; Gutman H; Cohen L; Gez R; Kadar T; Dachir S
Exp Eye Res; 2018 Jun; 171():183-191. PubMed ID: 29548928
[TBL] [Abstract][Full Text] [Related]
36. Corneal neovascularization and contemporary antiangiogenic therapeutics.
Hsu CC; Chang HM; Lin TC; Hung KH; Chien KH; Chen SY; Chen SN; Chen YT
J Chin Med Assoc; 2015 Jun; 78(6):323-30. PubMed ID: 25687646
[TBL] [Abstract][Full Text] [Related]
37. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
[TBL] [Abstract][Full Text] [Related]
38. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas.
Oh JY; Kim MK; Shin MS; Lee HJ; Lee JH; Wee WR
Curr Eye Res; 2009 Feb; 34(2):85-91. PubMed ID: 19219678
[TBL] [Abstract][Full Text] [Related]
39. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
[TBL] [Abstract][Full Text] [Related]
40. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model.
Mirabelli P; Peebo BB; Xeroudaki M; Koulikovska M; Lagali N
Exp Eye Res; 2014 Aug; 125():118-27. PubMed ID: 24933712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
